乳腺癌中MCM7表达及其及新辅助化疗关系探究.docVIP

乳腺癌中MCM7表达及其及新辅助化疗关系探究 　 作者：戴文斌，黄平，任占平，石吉吉，张芫，杨立 【摘要】 目的 探讨乳腺癌新辅助化疗前后MCM7蛋白的表达状况，分析其与化疗效果的关系。方法 采用免疫组织化学法检测55例乳腺癌新辅助化疗前后标本中MCM7的表达。结果 新辅助化疗有效率为76.36%。化疗前MCM7蛋白阳性表达显著高于化疗后(Plt;0.01)。化疗有效组(42例增殖期)MCM7蛋白阳性表达显著高于无效组(13例静止期)(Plt;0.01)。结论 ET方案新辅助化疗有较好的疗效，可能通过抑制MCM7蛋白的表达来阻止乳腺癌细胞的增殖。MCM7蛋白高表达者化疗更为敏感，MCM7可作为临床指导乳腺癌化疗并预测化疗敏感性的分子生物学指标。 【关键词】 乳腺肿瘤;化学疗法，辅助;MCM7蛋白 　　Abstract: Objective To study the expressions of MCM7 before and after neoadjuvant chemotherapy in patients with breast cancer, and to analyze its relationship with response to neoadjuvant chemotherapy. Methods An immunohistochemistry was used to measure the expressions of MCM7 before and after neoadjuvant chemotherapy for 55 cases of breast cancer. Results The overall response rate to neoadjuvant chemotherapy was 76.36%. The positive expression of MCM7 before neoadjuvant chemotherapy was significantly higher than that after neoadjuvant chemotherapy (Plt;0.01). The positive expression of MCM7 in the group of response to neoadjuvant chemotherapy (42 cases in proliferative phase) was significantly higher than that of no response to neoadjuvant chemotherapy (13 cases in quiescence phase) (Plt;0.01). Conclusion Neoadjuvant chemotherapy with ET regimen is effective, and it may inhibit the proliferation of breast cancer cell by down-regulation of the expression of MCM7. Patients with high expression of MCM7 were more likely to respond to chemotherapy. The expression of MCM7 as biological marker could be a guide for chemotherapy and prediction for its response to chemotherapy in breast cancer. 　　Key words: breast neoplasms; chemotherapy, neoadjuvant; MCM7 protein 　　乳腺癌是妇女最常见的恶性肿瘤之一，其发生、发展与细胞的异常增殖有关。新辅助化疗是乳腺癌综合治疗的重要组成部分，术前其主要通过抑制肿瘤细胞增殖、杀灭肿瘤细胞，从而缩小肿瘤体积，降低肿瘤分期、分级。了解乳腺癌对化疗药物的敏感性，有利于术后治疗方案的选择。但新辅助化疗前后乳腺癌细胞增殖状况的判断和评价标准及其与临床疗效评价的关系仍不十分清楚，寻找有效的细胞增殖标志物作为客观评价新辅助化疗效果及预后的指标是当前研究的热点。本研究采用免疫组织化学技术检测新辅助化疗前后乳腺癌MCM7的表达变化，探讨其与化疗效果的关系及作为乳腺癌新辅助化疗预测因子的意义。 　　1 对象与方法 　　1.1 对象 选取我院2005年1月～2008年12月可手术的原发性乳腺癌患者55例，均为女性，年龄25～74岁